Coeptis Therapeutics Holdings Inc./$COEP
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Ticker
$COEP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6
ISIN
US19207A2078
Website
COEP Metrics
BasicAdvanced
$26M
-
-$4.39
-0.58
-
Price and volume
Market cap
$26M
Beta
-0.58
52-week high
$12.50
52-week low
$6.26
Average daily volume
30K
Financial strength
Current ratio
0.823
Quick ratio
0.755
Long term debt to equity
2.263
Total debt to equity
27.339
Interest coverage (TTM)
-41.89%
Profitability
EBITDA (TTM)
-10.143
Gross margin (TTM)
28.18%
Net profit margin (TTM)
-15,697.97%
Operating margin (TTM)
-17,788.71%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-80.63%
Return on equity (TTM)
-357.37%
Valuation
Price to revenue (TTM)
267.515
Price to book
3.89
Price to tangible book (TTM)
4.21
Price to free cash flow (TTM)
-2.365
Free cash flow yield (TTM)
-42.29%
Free cash flow per share (TTM)
-316.33%
Growth
Earnings per share change (TTM)
-60.23%
3-year earnings per share growth (CAGR)
-56.32%
COEP News
AllArticlesVideos
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
GlobeNewsWire·1 week ago
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
GlobeNewsWire·1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coeptis Therapeutics Holdings Inc. stock?
Coeptis Therapeutics Holdings Inc. (COEP) has a market cap of $26M as of July 04, 2025.
What is the P/E ratio for Coeptis Therapeutics Holdings Inc. stock?
The price to earnings (P/E) ratio for Coeptis Therapeutics Holdings Inc. (COEP) stock is 0 as of July 04, 2025.
Does Coeptis Therapeutics Holdings Inc. stock pay dividends?
No, Coeptis Therapeutics Holdings Inc. (COEP) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Coeptis Therapeutics Holdings Inc. dividend payment date?
Coeptis Therapeutics Holdings Inc. (COEP) stock does not pay dividends to its shareholders.
What is the beta indicator for Coeptis Therapeutics Holdings Inc.?
Coeptis Therapeutics Holdings Inc. (COEP) has a beta rating of -0.58. This means that it has an inverse relation to market volatility.